Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045149 | 1.00 | IDH1 (0.43) | IDH1AAK1CYP2C19CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2714340 | 0.99 | IDH1 (0.43) | IDH1AAK1CYP2C19CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL15350476 | 0.89 | AAK1 (0.40) | IDH1AAK1CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL17244906 | 0.88 | IDH1 (0.45) | IDH1AAK1CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL28080965 | 0.87 | SCN9A (0.42) | IDH1AAK1SCN9A | |
| Hydrochloric Acid SCHEMBL15350461 | 0.86 | SCN9A (0.42) | IDH1AAK1SCN9A | |
| Hydrochloric Acid SCHEMBL15351153 | 0.85 | IDH1 (0.34) | IDH1AAK1CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4550347 | 0.84 | AAK1 (0.39) | IDH1AAK1CYP2C19PTGS2CYP17A1 | |
| SCHEMBL4550322 | 0.84 | AAK1 (0.39) | AAK1CYP2C19PTGS2CYP17A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2715008 | 0.82 | AAK1 (0.39) | IDH1AAK1CYP2C19PTGS2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | IDH1 1869/4885AAK1 2999/4885CYP2C19 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.